Navigation Links
Phase III pivotal results presented of VYVANSE to treat ADHD in adults
Date:5/8/2008

WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints.

"Adults with ADHD often find it challenging to focus and organize during the day. The disorder may impact many aspects of their lives from career to family and personal commitments," said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD program at the NYU Langone Medical Center, associate professor of psychiatry, neurology and child and adolescent psychiatry at the New York University School of Medicine, as well as author of Scattered Minds: Help and Hope for Adults with ADHD (G. P. Putnam's Sons 2006). "This study demonstrated that VYVANSE significantly improved ADHD symptoms in adults, including inattention, such as the ability to focus, organize and complete tasks, which are essential during an adult day, as well as hyperactivity, such as restlessness, and impulsivity."

This double-blind, placebo-controlled, four-week, forced-dose study in 414 adults aged 18 to 55 years showed that treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) provided a significant reduction in ADHD Rating Scale (ADHD-RS-IV) scores within one week that were observed throughout the full treatment period. At endpoint, VYVANSE demonstrated a significant improvement in ADHD symptoms, based on a 43 percent reduction in ADHD-RS scores. This is the largest placebo-controlled stimulant trial of ADHD in adults conducted to date.

Additional Study Findings Investigators also measured the efficacy of VYVANSE with the Clinical Global Impressions-Improvement (CGI-I) scale and found that the percentage of subjects taking VYVANSE rated "much improved" or "very much improved"
'/>"/>

Contact: Lucia Lodato
lucia.lodato@porternovelli.com
917-617-3058
Porter Novelli
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
2. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
3. Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting
4. Wal-Mart Launches Phase Three of $4 Prescription Program
5. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
6. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
7. Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
8. QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension
9. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
10. Many Phase 3 Cancer Drug Trials Yield Effective Medicines
11. Cancer treatments in phase 3 trials successful up to half of the time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... to have beneficial effects as sleep aids and calming remedies, which help to improve ... the result of a great deal of research in the field of regenerative medicine ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... Kall has been promoted from Administrative assistant to Executive Assistant to CEO Mitch ... with a proven professional, focused on your goals. Kathleen graduated from Florida ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at ... Community Colleges , will be hosting a Job Expo to provide a professional, open ... The Expo has expanded to much more than just a typical job and career ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a ... N.Y. "I specialize in manual therapy, and my invention will provide headache sufferers ... for additional muscle dysfunction throughout the body." , They developed THE RELIEVER to ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President ... to increase acceptance of the chiropractic field in the military. All too often VA ... Although Chiropractic was made available to the VA program over a decade ago, the ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... flush-and-forget-it indoor plumbing to be the pinnacle of ... far better solution for many parts of the ... , Associate Professor David Watkins, Professor James Mihelcic ... Sustainable Futures Institute analyzed worldwide barriers to sanitation. ...
... a safety hazard to the public, agency says , , TUESDAY, ... Administration has sent letters warning more than two dozen companies ... cure cancer. , The agency is also cautioning consumers not ... tonics, black salves, and creams, and are sold under various ...
... Synovics,Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a ... Report,with the Securities and Exchange Commission. Consolidated gross ... 2008 were $6,121,632 compared,to $5,713,761 for the same ... strong growth of the over-the-counter (OTC) product line ...
... Parks Associates, leading analysts will,explore the implications of ... in homes as a kickoff to CONNECTIONS(TM): The,Digital ... Roundtable: Top Trends to Watch, Tuesday, June 24,will ... focus on trends in,broadband and access services, video ...
... is available in Spanish . , The use ... to regenerate the bone and hasten the integration between the ... reduce from six months to two weeks the wait time ... the oral implant., This advance has been the resulto f ...
... Show in New York City from June ... ... for those with food allergies, are lactose intolerant, vegetarians,vegans, celiacs and health ... an exciting variety of 59 types of sauces,that include stir-fry sauces, dipping ...
Cached Medicine News:Health News:FDA Warns Companies to Stop Selling Fake Cancer Cures 2Health News:FDA Warns Companies to Stop Selling Fake Cancer Cures 3Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 2Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 3Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 4Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 5Health News:Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM) 2Health News:Scientists from Granada drastically reduce the wait time for new teeth implant 2Health News:WORLDFOODS Provides All Natural Authentic Asian Sauces That Cater to Vegetarians, Celiacs and Those With Food Allergies 2
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rktnl9/investigation ... "Investigation Report on China,s Insulin Aspart Market, 2010-2019" ... by Novo Nordisk, insulin aspart (under the trade ... the treatment of diabetes. Compared with human insulin, ... starts working fast and reports higher peak of ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... CALGARY, June 20, 2007 /PRNewswire-FirstCall/ - SemBioSys,Genetics ... portfolio of,therapeutic proteins for metabolic and cardiovascular ... a scientific poster and,abstract at the 67th ... in Chicago. The Company's poster will disclose,recent ...
... Follow,Presentation, DANBURY, Conn., June 20, 2007 /PRNewswire-FirstCall/ -- ... of its,leading product candidate, VIAject(TM), at the 67th ... held in,Chicago, June 22 through June 26. , ... place on June 22,from 4:15 - 6:15pm CST, ...
Cached Medicine Technology:SemBioSys to present new data at American Diabetes Association,annual meeting 2SemBioSys to present new data at American Diabetes Association,annual meeting 3Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 2Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 3
... a complete physician preference card system as ... for all the supply management requirements of ... system combined with a broad array of ... cart and operating suite supply and charge ...
Easy to Use manual vacuum system features a pumping mechanism that can be operated with one hand....
... Total TTC® is a complete ophthalmic system ... Color coded function modes with clear LED ... assures an easy to operate and user ... footswitch provides the surgeon complete control of ...
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Medicine Products: